A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma

NCT00492752 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

226

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Hepatocellular

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)
DRUG: Placebo

Sponsor

Bayer